Betrixaban vs Enoxaparin: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.177 | 0.165 | 0.189 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.166 | 0.154 | 0.178 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | 0.0113 | -0.00583 | 0.0284 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 1.07 | 0.967 | 1.18 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 1.08 | 0.96 | 1.22 | log | ClinicalTrials.gov | |
| Number needed to harm, for one more participant with a serious adverse event on Betrixaban than on Enoxaparin | 88.5 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Betrixaban | Daily oral (PO) betrixaban capsules for 35 to 42 days and subcutaneous (SQ) injections of enoxaparin placebo for 10 ± 4 days | 657 | 3,716 | EG000 | ClinicalTrials.gov |
| Group 2 | Enoxaparin | Daily subcutaneous (SQ) injections of enoxaparin for 10 ± 4 days and oral (PO) betrixaban placebo capsules for 35 to 42 days | 615 | 3,716 | EG001 | ClinicalTrials.gov |
Harm 2
| Field | Value | Source |
|---|---|---|
| What it counts | Total, serious adverse events | ClinicalTrials.gov |
| Time frame | From first dose date (including) till the end of study | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study) | ClinicalTrials.gov |
| NCT number | NCT01583218 | ClinicalTrials.gov |
| Phases | PHASE3 | ClinicalTrials.gov |
| Conditions | Venous Thromboembolism (VTE) | ClinicalTrials.gov |
| Interventions | Betrixaban, Enoxaparin | ClinicalTrials.gov |
| Lead sponsor | Portola Pharmaceuticals | ClinicalTrials.gov |
| Results first posted | 2017-09-20 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT01583218?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.